Observational studyBMC oral health2025
Salivary levels of suPAR, HIF-1α and TNF-α in different grades of stage III periodontitis.
Observational study in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06430450 (Determination of Salivary Soluble Urokinase Plasminogen Activator Receptor), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Determination of Salivary Soluble Urokinase Plasminogen Activator Receptor (SuPAR), Hypoxia-inducible Factor-1 Alpha (HIF-1α), E-cadherin, Galectin 3, IL-4, IL-10 and TNF-α Levels in Individuals With Different Degrees of Periodontal Disease
Who cites it
2 citing papers in PubMed.
- Diagnostic accuracy and smoking-driven modulation of salivary MMP-8, MMP-9, and HIF-1α in stage III grade B/C periodontitis: a cross-sectional study.Clinical oral investigations · 2026Article
- Association of Salivary HIF-1α Level With Epithelial and Mesenchymal Markers in Smokers and Nonsmokers With Periodontitis: A Case-Control Study.International journal of dentistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of the study is to evaluate saliva levels of Soluble urokinase plasminogen activator receptor (suPAR), Hypoxia-inducible factor-1 alpha (HIF-1α) and tumor necrosis factor-alpha (TNF-α) in stage III grade A, grade B, grade C periodontitis and periodontal health and to understand the roles of these molecules in periodontal inflammation process and also to compare the three biomarkers' discriminative efficacy in periodontal disease.
methodsA total of 80 individuals, 20 with stage III grade A periodontitis (group A), 20 with stage III grade B periodontitis (group B), 20 with stage III grade C periodontitis (group C) and 20 with healthy periodontium (group H) were recruited for this study. Full-mouth clinical periodontal measurements were recorded in periodontal charts. Whole saliva samples were collected to determine the levels of suPAR, HIF-1α and TNF-α in study groups using enzyme-linked immunosorbent assay (ELISA) method.
resultsThe saliva concentration of suPAR, HIF-1α, and TNF α was significantly higher in group A, group B, and group C compared with group H (p < .05). Additionally, salivary suPAR concentration was significantly higher in group C than in groups A and B (p < .05). Positive statistically significant correlations were observed between three biomarkers and all clinical parameters (p < .05).
conclusionsIncreased levels of saliva suPAR, HIF-1α, and TNF α suggest that these molecules may play a role in periodontitis. In addition, the higher salivary suPAR levels in grade C periodontitis compared to other grades suggest that suPAR may be one of the potential molecules that can be used to predict disease progression and periodontal disease classification.
trial registrationBefore starting the study, the study plan was uploaded to clinicaltrials.gov.tr and an identification number was obtained (Date: 21.05.2024, İdentification number: NCT06430450).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.